Sprint Bioscience Investor Relations Material

Sprint Bioscience AB is a Swedish biotechnology company focused on developing innovative cancer therapies. It specializes in drug discovery for oncology, leveraging a fragment-based drug discovery (FBDD) platform to accelerate the identification of promising molecules for cancer treatment. The company's research pipeline includes drug candidates targeting cancer metabolism and autophagy, with the aim of enhancing therapeutic approaches for hard-to-treat cancers. It is headquartered in Huddinge, Sweden, and its shares are listed on the Stockholm Stock Exchange.